Cancer Research AACR Conference on Molecular Diagnostics - 2008 Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baker, C. H.
Right arrow Articles by Fidler, I. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baker, C. H.
Right arrow Articles by Fidler, I. J.
[Cancer Research 62, 1996-2003, April 1, 2002]
© 2002 American Association for Cancer Research

Experimental Therapeutics

Blockade of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer1

Cheryl H. Baker, Carmen C. Solorzano and Isaiah J. Fidler2

Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

We determined whether concurrent blockage of vascular endothelial growth factor (VEGF) receptor and epidermal growth factor (EGF) receptor signaling by two novel tyrosine kinase inhibitors, PTK 787 and PKI 166, respectively, can inhibit angiogenesis and, hence, the growth and metastasis of human pancreatic carcinoma in nude mice. Highly metastatic human pancreatic carcinoma L3.6pl cells were injected into the pancreas of nude mice. Seven days later, groups of mice began receiving oral doses of PTK 787 and PKI 166 three times weekly. Some groups of mice also received i.p. injections of gemcitabine twice a week. The mice were necropsied when the control mice became moribund. Treatment with PTK 787 and PKI 166, with gemcitabine alone, or with the combination of PTK 787, PKI 166, and gemcitabine produced 69, 50, and 97% reduction in the volume of pancreatic tumors, respectively. Administration of protein tyrosine kinase inhibitors and gemcitabine also significantly decreased the incidence of lymph node and liver metastasis. The therapeutic efficacy directly correlated with a decrease in circulating proangiogenic molecules (VEGF, interleukin-8), a decrease in microvessel density, a decrease in proliferating cell nuclear antigen staining, and an increase in apoptosis of tumor cells and endothelial cells. Therapies produced by combining gemcitabine with either PKI 166 or PTK 787 were similar to those produced by combining gemcitabine with both PKI 166 and PTK 787. These results suggest that blockade of either epidermal growth factor receptor or VEGF receptor signaling combined with chemotherapy provides an effective approach to the therapy of pancreatic cancer.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
P. Beaudry, M. Nilsson, M. Rioth, D. Prox, D. Poon, L. Xu, P. Zweidler-Mckay, A. Ryan, J. Folkman, S. Ryeom, et al.
Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium
Mol. Cancer Ther., February 1, 2008; 7(2): 418 - 424.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
J. Tabernero
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents
Mol. Cancer Res., March 1, 2007; 5(3): 203 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Bianco, E. Giovannetti, F. Ciardiello, V. Mey, S. Nannizzi, G. Tortora, T. Troiani, F. Pasqualetti, G. Eckhardt, M. de Liguoro, et al.
Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer
Clin. Cancer Res., December 1, 2006; 12(23): 7099 - 7107.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. N. Landen Jr., C. Lu, L. Y. Han, K. T. Coffman, E. Bruckheimer, J. Halder, L. S. Mangala, W. M. Merritt, Y. G. Lin, C. Gao, et al.
Efficacy and Antivascular Effects of EphA2 Reduction With an Agonistic Antibody in Ovarian Cancer.
J Natl Cancer Inst, November 1, 2006; 98(21): 1558 - 1570.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Z. F. Yang, R. T.P. Poon, Y. Liu, C. K. Lau, D. W. Ho, K. H. Tam, C. T. Lam, and S. T. Fan
High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis.
Mol. Cancer Ther., September 1, 2006; 5(9): 2261 - 2270.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Abdelrahim, C. H. Baker, J. L. Abbruzzese, and S. Safe
Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
J Natl Cancer Inst, June 21, 2006; 98(12): 855 - 868.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Maruyama, M. Ono, A. Kawahara, T. Yokoyama, Y. Basaki, M. Kage, S. Aoyagi, H. Kinoshita, and M. Kuwano
Tumor Growth Suppression in Pancreatic Cancer by a Putative Metastasis Suppressor Gene Cap43/NDRG1/Drg-1 through Modulation of Angiogenesis.
Cancer Res., June 15, 2006; 66(12): 6233 - 6242.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner
Recent Advances in the Treatment of Malignant Astrocytoma
J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Amino, Y. Ideyama, M. Yamano, S. Kuromitsu, K. Tajinda, K. Samizu, H. Hisamichi, A. Matsuhisa, K. Shirasuna, M. Kudoh, et al.
YM-359445, an Orally Bioavailable Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor, Has Highly Potent Antitumor Activity against Established Tumors
Clin. Cancer Res., March 1, 2006; 12(5): 1630 - 1638.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. N. Rich, S. Sathornsumetee, S. T. Keir, M. W. Kieran, A. Laforme, A. Kaipainen, R. E. McLendon, M. W. Graner, B.K. A. Rasheed, L. Wang, et al.
ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors
Clin. Cancer Res., November 15, 2005; 11(22): 8145 - 8157.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. L. Kindler, G. Friberg, D. A. Singh, G. Locker, S. Nattam, M. Kozloff, D. A. Taber, T. Karrison, A. Dachman, W. M. Stadler, et al.
Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
J. Clin. Oncol., November 1, 2005; 23(31): 8033 - 8040.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. N. Younes, O. G. Yigitbasi, Y. W. Park, S.-J. Kim, S. A. Jasser, V. S. Hawthorne, Y. D. Yazici, M. Mandal, B. N. Bekele, C. D. Bucana, et al.
Antivascular Therapy of Human Follicular Thyroid Cancer Experimental Bone Metastasis by Blockade of Epidermal Growth Factor Receptor and Vascular Growth Factor Receptor Phosphorylation
Cancer Res., June 1, 2005; 65(11): 4716 - 4727.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Huang, M. Bennett, and P. E. Thorpe
A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice
Cancer Res., May 15, 2005; 65(10): 4408 - 4416.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Liu, R. T. Poon, Q. Li, T. W. Kok, C. Lau, and S. T. Fan
Both Antiangiogenesis- and Angiogenesis-Independent Effects Are Responsible for Hepatocellular Carcinoma Growth Arrest by Tyrosine Kinase Inhibitor PTK787/ZK222584
Cancer Res., May 1, 2005; 65(9): 3691 - 3699.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Kim, B. A. Schiff, O. G. Yigitbasi, D. Doan, S. A. Jasser, B. N. Bekele, M. Mandal, and J. N. Myers
Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788
Mol. Cancer Ther., April 1, 2005; 4(4): 632 - 640.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Zhang, E. Galardi, M. Duquette, M. Delic, J. Lawler, and S. Parangi
Antiangiogenic Treatment with the Three Thrombospondin-1 Type 1 Repeats Recombinant Protein in an Orthotopic Human Pancreatic Cancer Model
Clin. Cancer Res., March 15, 2005; 11(6): 2337 - 2344.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. W. Davis, R. Takamori, C. P. Raut, H. Q. Xiong, R. S. Herbst, W. M. Stadler, J. V. Heymach, G. D. Demetri, A. Rashid, Y. Shen, et al.
Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668
Clin. Cancer Res., January 15, 2005; 11(2): 678 - 689.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. K. Goudar, Q. Shi, M. D. Hjelmeland, S. T. Keir, R. E. McLendon, C. J. Wikstrand, E. D. Reese, C. A. Conrad, P. Traxler, H. A. Lane, et al.
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
Mol. Cancer Ther., January 1, 2005; 4(1): 101 - 112.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Hida, Y. Hida, D. N. Amin, A. F. Flint, D. Panigrahy, C. C. Morton, and M. Klagsbrun
Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities
Cancer Res., November 15, 2004; 64(22): 8249 - 8255.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. Takada, H. M. Weiss, O. Kretz, G. Gross, and Y. Sugiyama
HEPATIC TRANSPORT OF PKI166, AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR OF THE PYRROLO-PYRIMIDINE CLASS, AND ITS MAIN METABOLITE, ACU154
Drug Metab. Dispos., November 1, 2004; 32(11): 1272 - 1278.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. T. Tong, Y. Boucher, S. V. Kozin, F. Winkler, D. J. Hicklin, and R. K. Jain
Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors
Cancer Res., June 1, 2004; 64(11): 3731 - 3736.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Yokoi and I. J. Fidler
Hypoxia Increases Resistance of Human Pancreatic Cancer Cells to Apoptosis Induced by Gemcitabine
Clin. Cancer Res., April 1, 2004; 10(7): 2299 - 2306.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. J. Bruns, G. E. Koehl, M. Guba, M. Yezhelyev, M. Steinbauer, H. Seeliger, A. Schwend, A. Hoehn, K.-W. Jauch, and E. K. Geissler
Rapamycin-Induced Endothelial Cell Death and Tumor Vessel Thrombosis Potentiate Cytotoxic Therapy against Pancreatic Cancer
Clin. Cancer Res., March 15, 2004; 10(6): 2109 - 2119.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. Schoenberger, D. Grimm, P. Kossmehl, M. Infanger, E. Kurth, and C. Eilles
Effects of PTK787/ZK222584, a Tyrosine Kinase Inhibitor, on the Growth of a Poorly Differentiated Thyroid Carcinoma: An Animal Study
Endocrinology, March 1, 2004; 145(3): 1031 - 1038.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Dobrzanski, K. Hunter, S. Jones-Bolin, H. Chang, C. Robinson, S. Pritchard, H. Zhao, and B. Ruggeri
Antiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist
Cancer Res., February 1, 2004; 64(3): 910 - 919.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. M. Harari and S.-M. Huang
Searching for Reliable Epidermal Growth Factor Receptor Response Predictors: Commentary re M. K. Nyati et al., Radiosensitization by Pan-ErbB Inhibitor CI-1033 in Vitro and in Vivo. Clin. Cancer Res., 10: 691-700, 2004.
Clin. Cancer Res., January 15, 2004; 10(2): 428 - 432.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Fukahi, M. Fukasawa, G. Neufeld, J. Itakura, and M. Korc
Aberrant Expression of Neuropilin-1 and -2 in Human Pancreatic Cancer Cells
Clin. Cancer Res., January 15, 2004; 10(2): 581 - 590.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Abdollahi, K. E. Lipson, A. Sckell, H. Zieher, F. Klenke, D. Poerschke, A. Roth, X. Han, M. Krix, M. Bischof, et al.
Combined Therapy with Direct and Indirect Angiogenesis Inhibition Results in Enhanced Antiangiogenic and Antitumor Effects
Cancer Res., December 15, 2003; 63(24): 8890 - 8898.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. L. Janmaat and G. Giaccone
Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Oncologist, December 1, 2003; 8(6): 576 - 586.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Onn, T. Isobe, S. Itasaka, W. Wu, M. S. O'Reilly, W. Ki Hong, I. J. Fidler, and R. S. Herbst
Development of an Orthotopic Model to Study the Biology and Therapy of Primary Human Lung Cancer in Nude Mice
Clin. Cancer Res., November 15, 2003; 9(15): 5532 - 5539.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Ruggeri, J. Singh, D. Gingrich, T. Angeles, M. Albom, H. Chang, C. Robinson, K. Hunter, P. Dobrzanski, S. Jones-Bolin, et al.
CEP-7055: A Novel, Orally Active Pan Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models
Cancer Res., September 15, 2003; 63(18): 5978 - 5991.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
O. Stoeltzing, W. Liu, N. Reinmuth, F. Fan, A. A. Parikh, C. D. Bucana, D. B. Evans, G. L. Semenza, and L. M. Ellis
Regulation of Hypoxia-Inducible Factor-1{alpha}, Vascular Endothelial Growth Factor, and Angiogenesis by an Insulin-Like Growth Factor-I Receptor Autocrine Loop in Human Pancreatic Cancer
Am. J. Pathol., September 1, 2003; 163(3): 1001 - 1011.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. L. Weber, M. Doucet, J. E. Price, C. Baker, S. J. Kim, and I. J. Fidler
Blockade of Epidermal Growth Factor Receptor Signaling Leads to Inhibition of Renal Cell Carcinoma Growth in the Bone of Nude Mice
Cancer Res., June 1, 2003; 63(11): 2940 - 2947.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H. Uehara, S. J. Kim, T. Karashima, D. L. Shepherd, D. Fan, R. Tsan, J. J. Killion, C. Logothetis, P. Mathew, and I. J. Fidler
Effects of Blocking Platelet-Derived Growth Factor-Receptor Signaling in a Mouse Model of Experimental Prostate Cancer Bone Metastases
J Natl Cancer Inst, March 19, 2003; 95(6): 458 - 470.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S.-J. Kim, H. Uehara, T. Karashima, D. L. Shepherd, J. J. Killion, and I. J. Fidler
Blockade of Epidermal Growth Factor Receptor Signaling in Tumor Cells and Tumor-associated Endothelial Cells for Therapy of Androgen-independent Human Prostate Cancer Growing in the Bone of Nude Mice
Clin. Cancer Res., March 1, 2003; 9(3): 1200 - 1210.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Morioka, L. Weissbach, T. Vogel, G. P. Nielsen, G. T. Faircloth, L. Shao, and F. J. Hornicek
Antiangiogenesis Treatment Combined with Chemotherapy Produces Chondrosarcoma Necrosis
Clin. Cancer Res., March 1, 2003; 9(3): 1211 - 1217.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. S. O'Reilly
Targeting Multiple Biological Pathways as a Strategy to Improve the Treatment of Cancer
Clin. Cancer Res., November 1, 2002; 8(11): 3309 - 3310.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Matsuda, T. Idezawa, X. J. You, N. H. Kothari, H. Fan, and M. Korc
Multiple Mitogenic Pathways in Pancreatic Cancer Cells Are Blocked by a Truncated Epidermal Growth Factor Receptor
Cancer Res., October 1, 2002; 62(19): 5611 - 5617.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.